GlassScriptPhysician profile
Tong Liu
NPI 1922259399
$5,675.88
in general payments reported to CMS, 2019-2025
23 companies · $1,037 in 2025
The $1,037 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $594 · 2020: $705 · 2021: $946 · 2022: $1,019 · 2023: $730 · 2024: $645 · 2025: $1,037.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,412.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $687.06 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $679.27 | 2019-2025 | Brilinta, Farxiga, Lokelma |
| Amgen INC. | $596.66 | 2019-2025 | Repatha, Repatha |
| Abbott Laboratories | $580.57 | 2019-2025 | Aveir |
| Pfizer INC. | $402.69 | 2019-2025 | |
| Esperion Therapeutics, INC. | $356.56 | 2020-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $346.13 | 2020-2025 | Jardiance |
| Boston Scientific Corporation | $341.06 | 2019-2025 | Watchman Flx, Resonate El Icd Vr, Varithena Administration Pack |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $291.34 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $231.08 | 2019-2022 | |
| Amarin Pharma, INC. | $200.68 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $183.26 | 2021-2025 | Verquvo |
| Philips North America LLC | $180.04 | 2020-2023 | |
| Edwards Lifesciences Corporation | $136.96 | 2025 | Sapien 3 Ultra Resilia |
| Impulse Dynamics (USA) INC. | $132.24 | 2023 | Optimizer |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $104.48 | 2025 | |
| Novo Nordisk INC | $58.15 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $41.75 | 2019 | |
| Astellas Pharma US INC | $33.20 | 2019-2020 | |
| Medtronic, INC. | $31.14 | 2021-2025 | Venaseal |
| E.R. Squibb & Sons, L.L.C. | $29.76 | 2023-2025 | Camzyos, Eliquis |
| Baxter Healthcare | $17.02 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Alnylam Pharmaceuticals INC. | $14.78 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tong Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.